Clinical ResearchCoronary Heart DiseaseSex Differences in Presentation and Outcome Among Patients With Type 2 Diabetes and Coronary Artery Disease Treated With Contemporary Medical Therapy With or Without Prompt Revascularization: A Report From the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes)
Key Words
Abbreviations and Acronyms
Cited by (0)
The BARI 2D trial was funded by the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804). The BARI 2D trial received significant supplemental funding from GlaxoSmithKline and additional funding from Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.), AstellasPharma US, Inc., Merck & Co., Inc., Abbott Laboratories, Inc., and Pfizer, Inc. Medications and supplies were donated by Abbott Laboratories, Ltd., MediSense Products, Bayer Diagnostics, Becton, Dickinson and Company, J. R. Carlson Labs, Centocor, Inc., Eli Lilly and Company, LipoScience, Inc., Merck Sante, Novartis Pharmaceuticals Corporation, and Novo Nordisk, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, or the NIH. Dr. Korytkowski has received research support from Sanofi Aventis; and served as consultant to Regeneron. Dr. Magee has relationships with the American Diabetes Association, Esai, Boehringer-Ingelheim Cascade 8, Lilly REWIND, Washington DC Department of Health, AstraZeneca, American College of Cardiology DM & CVD CME program, and Quintiles/GE Centricity/Sanofi DIABETES FORWARD. Ms. Mighton has received compensation for training healthcare professionals and patients for Abbot Diabetes Care. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.